Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

This study is looking at how dopamine agonist medications (like cabergoline) used to treat prolactinomas (benign pituitary tumors that cause high prolactin levels) affect metabolism — including blood sugar, body weight, and cardiovascular risk markers. The aim is to better understand the metabolic effects of these commonly used medications. **You may be eligible if...** - You are an adult (18+) diagnosed with a prolactinoma (a pituitary tumor causing high prolactin) - You are either newly diagnosed and not yet on treatment, OR - You are already on cabergoline with prolactin levels now in the normal range **You may NOT be eligible if...** - Your high prolactin has a different cause - You have active substance use disorder, or a current or prior psychotic disorder - You are pregnant or breastfeeding - You have severe liver disease or severe kidney problems - You have a history of fibrosis affecting the lungs, heart lining, or abdomen - You need surgery for your tumor due to complications - You have a significant bowel condition or prior major gut surgery Talk to your doctor to see if this trial is right for you.